St. Paul, Minn.-based Kindeva is set to use its product development, regulatory affairs and manufacturing capabilities to help develop and commercialize CHI’s Aeolus dry-powder inhaler (DPI) platform technology, according to a news release.
Under the agreement, Kindeva will lead business and product development, including toxicology, process development and clinical design. CHI is slated to lead technology and device development, with both companies expecting the collaboration to lead to the development of multiple commercial products.
The companies will initially work with biopharmaceutical companies to evaluate drugs to use the platform to treat a range of respiratory diseases. Aeolus is designed to produce greater delivery efficiency and consistency independent of patient effort, which could leading to dose-sparing, according to CHI.
“With their unrivalled history and expertise in inhaled drug-delivery, Kindeva is the ideal partner to bring this revolutionary technology to the market,” CHI co-founder & CTO David Harris said in the release. “We’re excited to be working together to bring pharmaceutical customers’ products to market faster and at significantly reduced risk, and to offer the unique opportunity to deliver therapies beyond the reach of existing inhalation technology. We’re looking forward to redefining what inhalers can achieve.”
“We are excited to partner with CHI to develop and commercialize a truly novel DPI technology platform,” added Kindeva CEO Aaron Mann. “As leaders in inhalation product development, Kindeva understands that the industry must embrace the development of patient-centered technologies in order to meaningfully improve the way patients are treated.
“The Aeolus technology is designed to avoid many of the drawbacks of existing inhalation technology, addressing the need for efficiency, simplicity, and consistency of delivery, which lead to a more robust patient experience.”